MX2019003897A - Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos. - Google Patents

Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos.

Info

Publication number
MX2019003897A
MX2019003897A MX2019003897A MX2019003897A MX2019003897A MX 2019003897 A MX2019003897 A MX 2019003897A MX 2019003897 A MX2019003897 A MX 2019003897A MX 2019003897 A MX2019003897 A MX 2019003897A MX 2019003897 A MX2019003897 A MX 2019003897A
Authority
MX
Mexico
Prior art keywords
compositions
diagnosing
carbohydrate
methods
related disorders
Prior art date
Application number
MX2019003897A
Other languages
English (en)
Inventor
O Cope Frederick
Original Assignee
Cardinal Health 414 Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardinal Health 414 Llc filed Critical Cardinal Health 414 Llc
Publication of MX2019003897A publication Critical patent/MX2019003897A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a composiciones y métodos relacionados con moléculas que se dirigen a CD206 de cadena principal a base de carbohidratos. En la presente se describen composiciones para diagnosticar y tratar trastornos, por ejemplo, pero sin limitación, trastornos mediados por inflamasomas. Las composiciones descritas en la presente pueden actuar como moléculas portadoras para administrar agentes diagnósticos y terapéuticos.
MX2019003897A 2016-10-04 2017-10-04 Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos. MX2019003897A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662404111P 2016-10-04 2016-10-04
PCT/US2017/055211 WO2018067751A1 (en) 2016-10-04 2017-10-04 Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier

Publications (1)

Publication Number Publication Date
MX2019003897A true MX2019003897A (es) 2019-11-18

Family

ID=61757465

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003897A MX2019003897A (es) 2016-10-04 2017-10-04 Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos.

Country Status (6)

Country Link
US (2) US20180092998A1 (es)
EP (1) EP3522938A4 (es)
CA (1) CA3039519A1 (es)
IL (1) IL265727A (es)
MX (1) MX2019003897A (es)
WO (1) WO2018067751A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019018815A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. USE OF 99MTC-TILMANOCEPT AND ASSOCIATED MOLECULAR CONSTRUCTS FOR THE IDENTIFICATION AND DIAGNOSIS OF MALIGNANT TUMORS, AND FOR THE MONITORING OF ANTI-TUMOR THERAPEUTIC INTERVENTIONS
WO2022157373A1 (en) * 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions and kits for in vivo imaging of cardiac sarcoidosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ500273A (en) * 1997-03-18 2001-12-21 Nihon Schering Kabushiki Kaish Gadolinium (Gd) polymer MRI contrast agent responsive to environmental changes
ES2228536T3 (es) * 1999-05-14 2005-04-16 The Regents Of The University Of California Soporte macromolecular a base de dextrano para un farmaco y suministro de un agente de diagnosotico.
US20090311182A1 (en) * 2004-03-31 2009-12-17 Dong Wang Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
US9644039B2 (en) * 2006-03-24 2017-05-09 The Regents Of The University Of California Acid-degradable and bioerodible modified polyhydroxylated materials
CN114377143A (zh) * 2013-07-22 2022-04-22 康德乐健康414有限责任公司 用于诊断和治疗与表达cd206的细胞相关的病症的组合物、方法和药盒
WO2016011419A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
CA2955438A1 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Dextran conjugates for targeting macrophages and other mannose binding c-type lectin receptor expressing cells
CA2974634A1 (en) * 2015-01-21 2016-07-28 Navidea Biopharmaceuticals, Inc. Compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells

Also Published As

Publication number Publication date
CA3039519A1 (en) 2018-04-12
WO2018067751A1 (en) 2018-04-12
US20180092998A1 (en) 2018-04-05
IL265727A (en) 2019-05-30
US20210338848A1 (en) 2021-11-04
EP3522938A4 (en) 2020-06-24
EP3522938A1 (en) 2019-08-14

Similar Documents

Publication Publication Date Title
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2023000745A (es) Composiciones para usarse en el suministro de agentes biomacromoleculares.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
EA201890908A1 (ru) Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2017004838A (es) Composiciones de interleucina-15 y usos de estas.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2017001971A (es) Composiciones antimetanogenicas y sus usos.
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2016014559A (es) Compuestos para el tratamiento de cancer.
PH12019501224A1 (en) Compositions for treatment of polycystic kidney disease
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
PH12016501613B1 (en) Pyrazines modulators of gpr6
TW201713686A (en) Methods for preparing modified von Willebrand factor
MX2019003897A (es) Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos.
WO2018045078A3 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING LYMPHATIC SYSTEM DISORDERS
MX2018012545A (es) Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso.
MX2021007271A (es) Nuevas moleculas de acido nucleico conjugado y sus usos.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2020002147A (es) Composiciones útiles para la mejora del dolor.
PH12017500500A1 (en) C-20 steroid compounds, compositions and uses thereof to treat traumatic brain injury (tbi), including concussions